Skip to main content
. 2015 Nov 13;4(11):e002553. doi: 10.1161/JAHA.115.002553

Figure 9.

Figure 9

Cardiac sPLA 2 is a biological mediator and determinant of the cardiohepatic phenotype of matrix metalloproteinase 2–deficient mice. A, The increase in plasma sPLA 2 evoked by high‐performance liquid chromatography–isolated cardiac sPLA 2 from Mmp2 −/− donors was prevented by coadministering varesladib (10 mg/kg per day). B and C, Increased plasma sPLA 2 was associated with a cardiohepatic gene expression profile very similar to that of Mmp2 −/− mice. These changes were prevented by coadministering varespladib. n=4 mice per group. *P≤0.05 vs WT. † P≤0.05 vs WT+F6/F7 (donor: Mmp2 −/−). sPLA2 indicates secreted phospholipase A2; WT, wild type.